ChromaCode To Show New Data In Oncology and Blood Based Monitoring at the Association for Molecular Pathology 2023 Annual Meeting and Expo
Company's accepted scientific abstracts and corporate workshop to highlight the utility of HDPCR™ technology and the ChromaCode Cloud software in enabling best-in-class multiplexing and sample to answer in 24 hours
CARLSBAD, Calif., Oct. 31, 2023 /PRNewswire/ -- ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable solutions for laboratories, will present new data during a Corporate workshop and present two accepted scientific abstracts at the Association for Molecular Pathology (AMP) 2023 annual meeting, being held at the Salt Palace Convention Center in Salt Lake City, Utah, from November 14-18, 2023.
"The ChromaCode team is proud to participate in this year's preeminent conference for molecular diagnostics, AMP 2023. Our accepted scientific abstracts demonstrate the excellent performance of the HDPCR technology in solid and heme malignancies. At the Corporate Workshop, we will be revealing new data showcasing the potential of HDPCR enabled multiplexing and ChromaCode software in transplant and minimal residual disease. We look forward to engaging with fellow attendees at these presentations and at our Booth (1700)" stated Mark McDonough, Chief Executive Officer at ChromaCode.
The title of the corporate workshop in Room 255EF at the Salt Palace Convention Center on November 15 from 12:00- 12:50 p.m. MT is "HDPCR–High content multi-analyte assays in blood and FFPE with 24-hour turnaround, using existing dPCR instruments; performance in molecular profiling, monitoring and MRD". The workshop consists of four presentations on HDPCR, NSCLC applications, Transplant Rejection Testing and the Precision Oncology Platform, with further information on the presentations and presenters below:
According to Padma Sundar, Chief Business Officer at ChromaCode "We are thrilled to have the opportunity to come to Salt Lake City and to AMP 2023. This is the perfect venue in which to present our genomic multiplexing platform and its applications and to meet with potential collaborators and lab customers. We encourage anyone interested to sign up and attend our workshop where we will share new data on HDPCR applications, and stop by our booth and poster presentations to learn more about the exciting work we do".
ChromaCode is an innovator in genomics multiplexing platform technology, providing laboratory solutions with its proven HDPCR™ technology. HDPCR™ is a revolutionary approach allowing for deep multiplexing of biomarkers in a single, rapid, cost-effective assay for multiple sample types on standard laboratory dPCR platforms. This adaptable technology, deployed with ChromaCode's cloud-based analysis, enables laboratories worldwide to affordably conduct testing internally and produce high quality results with demonstrated high concordance with next generation sequencing (NGS) based testing, increasing accessibility of diagnostics with a cost effective and scalable solution. For more information visit ChromaCode.com or on LinkedIn and Twitter.
Media Contact- ChromaCode
View original content to download multimedia:https://www.prnewswire.com/news-releases/chromacode-to-show-new-data-in-oncology-and-blood-based-monitoring-at-the-association-for-molecular-pathology-2023-annual-meeting-and-expo-301971938.html
SOURCE ChromaCode, Inc.